STAT

With a closer look at immune systems, scientists hope to steer infants back onto a healthy track

What if you could give vulnerable infants an immunological tweak to steer them back onto a healthy track?

What if you could lower the risk that newborns would develop life-threatening infections? Optimize — even personalize — the timing of vaccines given early in life? Figure out which babies aren’t developing competent immune systems or are at risk of type 1 diabetes? What if you could give them an immunological tweak to steer them back onto a healthy track?

New research suggests those “what ifs?” may someday be reality.

A , from researchers at Boston Children’s Hospital and colleagues in several other countries, used minute amounts of blood drawn in the first week of life to

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks